Pull to refresh
Logo
City Therapeutics files for Nasdaq IPO to fund RNAi pipeline

City Therapeutics files for Nasdaq IPO to fund RNAi pipeline

Money Moves

RNA interference biotech founded by Alnylam's former chief seeks public listing under ticker CTY

Yesterday: Amended S-1 sets price range

Overview

Updated 1 hour ago

Cambridge biotech City Therapeutics filed Friday to raise up to $184.7 million in a Nasdaq initial public offering, marketing 9.7 million shares at $17 to $19 each. The company, founded in 2023 by Alnylam Pharmaceuticals' former founding chief executive, develops RNA interference drugs that silence disease-linked genes.

The offering would value City near $956 million at the top of the range. Proceeds would fund three clinical programs and the drug-discovery platform, with existing cash covering operations into late 2028.

Why it matters

This IPO tests whether public investors fund RNA interference startups after Alnylam's success — a signal for the gene-silencing field.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

$184.7M
Maximum gross IPO proceeds
9.72 million shares at $19, the top of the price range
$956M
Implied valuation at top of range
Based on $19 per share and roughly 50 million shares outstanding after the offering
$238.8M
Private capital raised since founding
From investors including Arch Venture Partners (about 35%) and Fidelity (about 10%)
$53.4M
Net loss, first half of 2026
Against $6.4 million in collaboration revenue; accumulated deficit of $142.5 million

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

People Involved

Organizations Involved

Timeline

July 2023 October 2026

3 events Latest: Yesterday
  1. Amended S-1 sets price range

    Latest Filing

    Amendment sets $17-$19 per share, 9.72 million shares, projected $956 million valuation at top of range.

  2. Initial S-1 filed with SEC

    Filing

    Company files initial IPO registration statement with the Securities and Exchange Commission.

  3. City Therapeutics founded

    Founding

    Company launched in Cambridge by John Maraganore and co-founders, with $238.8 million eventually raised privately.

Scenarios

1

City Therapeutics prices its IPO at or near the midpoint

Likely Resolves by Nov 30, 2026

Discussed by: Quartz, MedPharmaNews, and the underwriting syndicate's syndication desk

The offering prices around $18 per share, raising about $175 million gross and roughly $158.3 million in net proceeds. The company lists on the Nasdaq Global Market under CTY, with the overallotment option adding up to 1.46 million more shares if exercised.

2

City Therapeutics cuts its offering size or price

Possible Resolves by Nov 30, 2026

Discussed by: Market analysts tracking the biotech IPO window

If investor demand softens between filing and pricing, City may lower the price range or reduce shares offered below 9.72 million. This happened to several biotech IPOs in 2022, when a cold market forced companies to price at the bottom of ranges or shrink deals.

3

IPO withdrawn or indefinitely delayed

Unlikely Resolves by End of 2026

Discussed by: Observers of biotech IPO market cycles

A sharp market downturn or sudden volatility could push City to pull the offering, as several biotechs did in late 2022 when the IPO window slammed shut. The company would retain its $141.9 million cash cushion and revisit listing later.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

May 2004

Alnylam Pharmaceuticals IPO (2004)

Alnylam went public two years after its founding, before any RNAi drug had been approved. The company spent 14 years navigating development failures and delivery challenges before winning FDA approval for ONPATTRO in 2018, the first RNA interference therapeutic on the market.

Then

The IPO funded early research, but the field's promise took over a decade to prove in patients.

Now

Alnylam validated the RNAi approach and established the GalNAc conjugation technology for liver-targeted delivery that City Therapeutics now uses.

Why this matters now

City's lead candidate CITY-FXI uses the same approach Alnylam pioneered. John Maraganore, who led Alnylam through its own IPO and first approval, now chairs City.

December 2018

Moderna IPO (2018)

Moderna raised more than $600 million in its December 2018 IPO at $23 a share, valuing the company near $7.5 billion despite having no approved products. The offering was a bet on the versatility of its messenger RNA platform.

Then

Critics called the valuation rich for a company with no revenue; shares initially traded below the offering price.

Now

The platform proved out two years later when Moderna's COVID-19 vaccine became one of the most widely used in the world.

Why this matters now

Like Moderna, City is a platform company — its 'City Platform' spans multiple RNAi triggers beyond its lead candidates. The IPO tests whether investors pay for platform optionality, not just near-term products.

Sources

(7)